Theresa A Deisher

This inventor holds 35 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Biologics Development. Top assignees: Zymogenetics, Inc., Avm Biotechnology, LLC, Immunex Corporation. Active years: 1999-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Theresa A Deisher. Retrieved from https://idiyas.com/inventor/theresa-a-deisher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 35 (Patent Applications = 6)

% Patents Active = 71.4

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 2.1

ph-index = 8

Forward Citations = 209(Granted Patents)

Company Filing History:

Avm Biotechnology, LLC

4. 1 out of 834,570

Other

patents

Years Active: 1999-2026

Loading Chart...

Areas of Expertise:

Glucocorticoid Formulation

ICAM-Modulating Agents

Immunoablative Therapies

Cellular Immunotherapy

Stem Cell Inhibition

Biologics Production

Inflammation Reduction

FGF Homologs

Motilin Homologs

Disintegrin Homologs

Type II Diabetes Treatment

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653891 - Stable glucocorticoid formulation (2026-06-16),

2. 12648952 - Methods of treatment using ICAM-modulating agents (2026-06-09),

3. 12048705 - Immunoablative therapies (2024-07-30),

4. 11446314 - Immunoablative therapies (2022-09-20),

5. 11219628 - Replacement of cytotoxic preconditioning before cellular immunotherapy (2022-01-11),

6. 10426740 - Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues (2019-10-01),

7. 10030230 - Personalized production of biologics and method for reprogramming somatic cells (2018-07-24),

8. 9962408 - Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues (2018-05-08),

9. 9512200 - Personalized production of biologics and method for reprogramming somatic cells (2016-12-06),

10. 8529894 - Methods of reducing inflammation in cardiomyopathy (2013-09-10),

11. 8349590 - FGF homologs compositions and uses thereof (2013-01-08),

12. 8153586 - FGF homologs compositions and uses thereof (2012-04-10),

13. 7977309 - Methods of using motilin homologs (2011-07-12),

14. 7671020 - Methods of increasing cartilage deposition using FGF homologs (2010-03-02),

15. 7563438 - FGF homologs and antibodies thereto (2009-07-21),

Title: The Innovative Contributions of Theresa A. Deisher in Immunoablative Therapies

Introduction: Theresa A. Deisher is a distinguished inventor based in Seattle, WA, renowned for her significant contributions to the field of biotechnology. With an impressive portfolio of 33 patents, she has been instrumental in advancing immunoablative therapies that target diseases mediated by immune cells, particularly lymphocytes.

Latest Patents: Among her latest innovations is the development of pharmaceutical compositions that incorporate glucocorticoids for the treatment of various diseases through immunoablation. These compositions are particularly valuable for conditions reliant on the modulation of immune responses, showcasing her commitment to improving therapeutic options in the medical field.

Career Highlights: Theresa has held key positions in notable biotechnology companies such as Zymogenetics, Inc. and Avm Biotechnology, LLC. Her work in these organizations has contributed to pioneering research and development initiatives within the biotechnology sector, significantly influencing the pathways to innovative treatments.

Collaborations: Throughout her career, Theresa A. Deisher has collaborated with esteemed colleagues including Paul O. Sheppard and Darrell C. Conklin. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking therapies and expands the breadth of innovation in immune-related treatments.

Conclusion: Theresa A. Deisher stands out as a leading figure in the realm of biotechnology, making substantial contributions through her patents and collaborations. Her work on immunoablative therapies not only underscores her expertise as an inventor but also highlights the critical role that innovation plays in transforming medical treatments. As the landscape of biotechnology continues to evolve, Theresa’s contributions are poised to leave a lasting impact on the field.

Profile summary based on public USPTO records.